Primary and secondary outcomes at 90–120 days for study participants treated with tenecteplase versus alteplase
| Tenecteplase (n=194) | Alteplase (n=184) | Unadjusted risk ratio (95% CI) | Adjusted risk ratio (95% CI)* | |
| Primary outcome | ||||
| Modified Rankin Scale score 0–1 at 90–120 days, n (%) | 100 (51.8) | 86 (47.5) | 1.09 (0.88 to 1.23) | 1.14 (0.92 to 1.40) |
| Secondary outcomes | ||||
| Modified Rankin Scale score 0–2 at 90–120 days, n (%) | 143 (74.1) | 126 (69.6) | 1.06 (0.93 to 1.20) | 1.09 (0.94 to 1.26) |
| Modified Rankin Scale score at 90–120 days, median (IQR) | 1 (0–3) | 2 (1–3) | 0.74 (0.52 to 1.07) | 0.69 (0.47 to 1.00)† |
| EQ-5D VAS at 90–120 days, median (IQR) | 75 (61–86) | 75 (60–90) | 0.62 (-3.50 to 4.77) | 0.99 (0.97-1.02)‡ |
| Return to baseline function, n (%) | 80 (42.5) | 61 (35.3) | 1.20 (0.92 to 1.56) | 1.20 (0.90 to 1.59) |
| Endovascular thrombectomy utilisation, n (%) | 22 (11.3) | 15 (8.1) | 1.39 (0.74 to 2.59) | 0.88 (0.53 to 1.47) |
| eTICI 2b/3 at first angiographic run, n (%) | 8 (36.4) | 1 (6.7) | 5.45 (0.75 to 39.21) | 6.68 (0.49 to 90.57) |
| eTICI 2b/3 at final angiographic run, n (%) | 9 (60) | 21 (95.4) | 1.59 (1.04 to 2.42) | 1.57 (0.58 to 4.25) |
| Length of hospital stay, median days (IQR) | 4 (2–8) | 4 (2–7) | −0.47 (−2.6 to 1.70) | 0.86 (0.79 to 0.93)‡ |
Data are n (%), median (IQR), mean (SD) or effect estimate with 95% CI in parentheses.
*Adjusted for age, sex, occlusion location as fixed-effects variables and participating site as a random-effects variable.
†Common OR is the OR for a unit increase in the modified Rankin Scale score for tenecteplase versus alteplase.
‡Risk ratio using mixed-effects linear regression model adjusted for age, sex, occlusion location as fixed-effects variables and participating site as a random-effects variable.
eTICI, expanded treatment in cerebral infarction; VAS, Visual Analogue Scale.